NCT01754870撤回2 期
HO11415: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
CLL/SLL is an incurable disease with conventional chemotherapy, and there are limited treatment options available for patients who have become refractory to fludarabine- and alkylating-agent based regimens. Bendamustine is a recently FDA-approved agent with significant activity in CLL/SLL, including significant activity in the setting of fludarabine-refractory disease. However, durations of remission following bendamustine/rituximab combination therapy tend to be short in patients with heavily pre-treated disease or who have already received rituximab.
The incorporation of a maintenance therapy to overcome the shorter remission durations in this population is a reasonable and feasible option. In considering potential options for treatment of CLL/SLL as a maintenance strategy following induction chemotherapy, lenalidomide and rituximab are appealing options based on their convenient dosing schedules and recent evidence of acceptable toxicity and promising efficacy in combination therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed CLL/SLL.
- •Understand and voluntarily sign an informed consent document.
- •Age greater than or equal to 18 years at the time of signing the informed consent document.
- •Subjects must have documented relapsed or refractory CLL/SLL.
- •Relapsed disease is defined as progressive disease after achieving a complete or partial response to the most recent therapy.
- •Refractory disease is defined as less than a partial response to the most recent therapy.
- •Subjects must have received ≥1 prior chemotherapy regimen for their disease. Prior therapy with single-agent rituximab does not meet criteria for a prior chemotherapy regimen (i.e., prior treatment must include cytotoxic chemotherapy agent).
- •In cases of SLL, subjects must have at least one bidimensionally measurable lesion at least ≥1.5 cm measured in one dimension.
- •Eastern Cooperative Oncology Group performance status of less than or equal to 2 at study entry
- •Laboratory test results within these ranges:
- •Absolute neutrophil count greater than or equal to 1500/μL
- •Platelet count great than or equal to 100,000/μL
- •Subjects with neutrophils <1500/μL or platelets <100,000/μL with splenomegaly or extensive bone marrow involvement as the etiology for their cytopenias are eligible
- •Subjects must have adequate renal function with a creatinine clearance of ≥40 mL/min as determined by the Cockcroft-Gault calculation
- •Total bilirubin less than or equal to 2X (times) upper limit laboratory normal (ULN); subjects with non-clinically significant elevations of bilirubin due to Gilbert's disease are not required to meet these criteria
- •Serum transaminases aspartate aminotransferase (AST) (SGOT) and (alanine aminotransferase) ALT (SGPT) less than or equal to 5X ULN
- •Serum alkaline phosphatase ≤5X ULN
- •Disease-free of prior malignancies for ≥2 years with the exception of basal or squamous cell skin carcinoma, carcinoma "in situ" of the breast or cervix, or localized prostate cancer (treated definitively with hormone therapy, radiotherapy, or surgery).
- •Life expectancy of at least 3 months.
- •All study participants must be willing to be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of Revlimid REMS® .
- •Subjects must not have a known history of hypersensitivity to mannitol.
- •Subjects may have received prior therapy with bendamustine or lenalidomide, but must not have disease that is refractory to bendamustine or lenalidomide.
- •Prior therapy with rituximab is permitted, even in the setting of rituximab-refractory disease.
- •Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (subjects intolerant to aspirin may use warfarin or low molecular weight heparin) if clinically indicated.
- •Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by Revlimid REMS® ) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. See Appendix: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods.
- •Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.
排除标准
- •Subjects may not have received >5 lines of prior therapy for their disease. Re-treatment with an identical regimen does not count as a new regimen.
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent document or complying with the protocol treatment.
- •Pregnant or breast-feeding females. Lactating females must agree not to breast-feed while taking lenalidomide.
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- •Subjects are not eligible if there is a prior history or current evidence of central nervous system or leptomeningeal involvement.
- •Use of any other experimental drug or therapy within 28 days of enrollment.
- •Known hypersensitivity to thalidomide.
- •The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- •Disease that is refractory to prior therapy with bendamustine or lenalidomide.
- •Concurrent use of other anti-cancer agents or treatments.
- •Known to be positive for HIV or infectious hepatitis (type B or C).
- •Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical or breast cancer, or other cancer from which the subject has been disease free for at least 2 years.
- •Severe or life-threatening anaphylaxis or hypersensitivity reaction when previously exposed to rituximab or other monoclonal antibody therapy.
- •Chronic hepatitis B or hepatitis C infection.
- •New York Heart Association class 3-4 heart failure.
研究组 & 干预措施
Bendamustine + Rituximab-->Rituximab and Lenalidomide
Experimental
Induction chemoimmunotherapy:
- Bendamustine 70 mg/m2 IV days 1 & 2 every 28 days X 6 cycles
- Rituximab 500 mg/m2 IV day 1 every 28 days X 6 cycles (375 mg/m2 IV cycle 1 only, day 1 or 2)
Maintenance phase:
- Rituximab 375 mg/m2 IV on day 1 of every odd-numbered 28 day cycle for a maximum of 12 doses during the maintenance phase.
- Lenalidomide 5 mg orally daily on days 1-28 of each 28-day cycle for 24 cycles (maintenance cycles 1-24); dose escalation to 10 mg orally daily will be allowed at the start of cycle 2 or at the start of any subsequent cycle in subjects with acceptable toxicities needed to escalate the dose of lenalidomide to 10 mg/day.
干预措施: Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance (Drug)
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: Up to 30 months
• The primary objective is progression-free survival for patients entering the maintenance therapy phase with rituximab and lenalidomide after induction therapy with bendamustine and rituximab. Progression is defined as radiographic or clinical progression as defined by the specified standard response criteria for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)or initiation of a new anti-neoplastic therapy in the absence of progression. Subjects with clinical evidence of progression prior to a planned disease assessment will be evaluated at the time of clinically suspected progression.
次要结局
- Toxicity(Up to 30 months)
- Overall survival(Up to 54 months)
- Objective Response Rates(Up to 30 months)
研究者
相似试验
已完成
2 期
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLLSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT00974233University of Wisconsin, Madison34
Unknown
不适用
Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT03847727Pirogov Russian National Research Medical University112
已完成
1 期
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)Non-Hodgkin's LymphomaChronic Lymphocytic LeukemiaNCT00864942Georgetown University28
撤回
2 期
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT00758693University of Kentucky
进行中（未招募）
2 期
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell LymphomaMantle Cell LymphomaNCT01661881Christine Ryan23